Discontinuation – no longer needing complement inhibition
Complement inhibition treatment discontinuation is a topic that Global Action has led on in the aHUS patient advocacy world for several…
Complement inhibition treatment discontinuation is a topic that Global Action has led on in the aHUS patient advocacy world for several…
Recently a novel article about complement inhibitor treatment discontinuation was published. Novel because of the research method used to produce its…
There are now licensed biosimilars to eculizumab available in Europe and also in the USA ( see previous article and further…
In making a choice aHUS patients’ preferences among treatments like eculizumab (and its biosimulars) , ravulizumab, crovalimab, and iptacopan it largely…
It is now just over 3 months since a discontinuing treatment decision making model was proposed to help aHUS patients make…
Introduction Atypical Hemolytic Uremic Syndrome (aHUS) is a rare, life-threatening disease that remains largely unfamiliar to the general public and even…
Without any further comment here is the model mentioned in the previous article ( which if you have not already seen…
You have had aHUS. The type of aHUS caused by uncontrolled complement, not the other type. You got access to a…